INDIANAPOLIS, Aug. 23, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC), a molecular imaging and solutions company specializing in nuclear cardiology and a leader in cardiac PET, announced today the Company is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference, held on September 12-15, at the New York Palace hotel in New York City.
Patrick Rooney, chief executive officer of Positron Corporation, will be presenting on Tuesday, September 14th. Details surrounding the presentation and audio webcast will be made available in the coming weeks.
For more information about the Rodman & Renshaw 12th Annual Healthcare Conference, go to: http://www.rodmanandrenshaw.com/conferences.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.